Table of contents
Forxiga is a medicine used to treat type 2 diabetes, chronic (long-term) heart failure and chronic kidney disease.
In type 2 diabetes, Forxiga is used in adults and children from 10 years of age whose condition is not controlled well enough. It is used with appropriate diet and exercise in patients who cannot take metformin (another diabetes medicine). It can also be used as ‘add-on’ treatment to other diabetes medicines.
In chronic heart failure (inability of the heart to pump enough blood around the body), Forxiga is used in adults who have symptoms of the disease. Forxiga is also used in adults with chronic kidney disease.
Forxiga contains the active substance dapagliflozin.
Forxiga : EPAR - Medicine overview (PDF/125.83 KB) (updated)
First published: 07/12/2012
Last updated: 06/03/2023
Forxiga : EPAR - Risk-management-plan summary (PDF/109.44 KB) (updated)
First published: 08/04/2019
Last updated: 01/03/2023
|Agency product number||
dapagliflozin propanediol monohydrate
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
|Date of issue of marketing authorisation valid throughout the European Union||
151 85 Sodertalje
03/02/2023 Forxiga - EMEA/H/C/002322 - WS/2299
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Drugs used in diabetes
Type 2 diabetes mellitus
Forxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance.
- in addition to other medicinal products for the treatment of type 2 diabetes.
For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.
Forxiga is indicated in adults for the treatment of symptomatic chronic heart failure.
Chronic kidney disease
Forxiga is indicated in adults for the treatment of chronic kidney disease.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 202216/12/2022
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 202115/10/2021
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 202016/10/2020
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 201901/02/2019